CAT-1004 regulatory update

FDA granted Orphan Drug designation to CAT-1004 from Catabasis to treat Duchenne muscular dystrophy (DMD). Catabasis plans to start Phase II testing in 1H15. The conjugate of salicylate and docosahexa...